142 related articles for article (PubMed ID: 36249051)
1. The impact of the COVID-19 pandemic on diagnosis and treatment of patients with soft tissue and bone sarcomas or aggressive benign musculoskeletal diseases: A single-center retrospective study (SarCorD study).
Onesti CE; Vari S; Nardozza F; Maggi G; Minghelli D; Rossi B; Sperati F; Checcucci E; Faltyn W; Cercato MC; Cosimati A; Biagini R; Ciliberto G; Ferraresi V
Front Oncol; 2022; 12():1000056. PubMed ID: 36249051
[TBL] [Abstract][Full Text] [Related]
2. Quality of life and emotional distress in sarcoma patients diagnosed during COVID-19 pandemic: a supplementary analysis from the SarCorD study.
Onesti CE; Vari S; Minghelli D; Nardozza F; Rossi B; Sperati F; Checcucci E; Faltyn W; Cercato MC; Cosimati A; Salvatori F; Biagini R; Ciliberto G; Ferraresi V; Maggi G
Front Psychol; 2023; 14():1078992. PubMed ID: 37333608
[TBL] [Abstract][Full Text] [Related]
3. Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain.
Carrillo-García J; Lacerenza S; Hindi N; García IC; Marquina G; Cano Cano JM; Trufero JM; Sevillano Tripero AR; Luis García T; Cuesta Rioboo MJ; Moura DS; Renshaw M; Mondaza-Hernández JL; Di Lernia D; Gutierrez A; Martin-Broto J
Ther Adv Med Oncol; 2024; 16():17588359231220611. PubMed ID: 38205079
[TBL] [Abstract][Full Text] [Related]
4. Impact of the COVID-19 on the surgical management of bone and soft tissue sarcoma: A systematic review.
Putro YAP; Magetsari R; Mahyudin F; Basuki MH; Saraswati PA; Huwaidi AF
J Orthop; 2023 Apr; 38():1-6. PubMed ID: 36875225
[TBL] [Abstract][Full Text] [Related]
5. The effect of delayed postoperative irradiation on local control of soft tissue sarcomas of the extremity and torso.
Schwartz DL; Einck J; Hunt K; Bruckner J; Conrad E; Koh WJ; Laramore GE
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1352-9. PubMed ID: 11955749
[TBL] [Abstract][Full Text] [Related]
6. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
7. [Histopathological diagnostic concordance in bone and soft tissue sarcomas between two comprehensive cancer centers from eastern and western Europe: a collaborative experience].
Somcutian O; Buiga R; Galatir M; Tudor Eniu D; Rachieru C; Coza D; Terrier P
Ann Pathol; 2015 Jan; 35(1):32-40. PubMed ID: 25541117
[TBL] [Abstract][Full Text] [Related]
8. Is There an Association Between Insurance Status and Survival and Treatment of Primary Bone and Extremity Soft-tissue Sarcomas? A SEER Database Study.
Smartt AA; Jang ES; Tyler WK
Clin Orthop Relat Res; 2020 Mar; 478(3):527-536. PubMed ID: 31390340
[TBL] [Abstract][Full Text] [Related]
9. Extremities Soft Tissue Sarcomas, more Common and as Dangerous as Bone Sarcomas.
Voltan K; Baptista AM; Etchebehere M
Rev Bras Ortop (Sao Paulo); 2021 Aug; 56(4):419-424. PubMed ID: 34483383
[TBL] [Abstract][Full Text] [Related]
10. Delayed Diagnosis Is the Primary Cause of Sarcoma Litigation: Analysis of Malpractice Claims in the United States.
Hwang R; Park HY; Sheppard W; Bernthal NM
Clin Orthop Relat Res; 2020 Oct; 478(10):2239-2253. PubMed ID: 32496320
[TBL] [Abstract][Full Text] [Related]
11. Delay in Diagnosis and Treatment of Primary Bone Tumors during COVID-19 Pandemic in Poland.
Kotrych D; Ciechanowicz D; Pawlik J; Szyjkowska M; Kwapisz B; Mądry M
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551524
[TBL] [Abstract][Full Text] [Related]
12. Early symptoms of bone and soft tissue sarcomas: could they be diagnosed earlier?
George A; Grimer R
Ann R Coll Surg Engl; 2012 May; 94(4):261-6. PubMed ID: 22613305
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
14. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
[TBL] [Abstract][Full Text] [Related]
15. Patients with an increased time to treatment initiation have a poorer overall survival after definitive surgery for localized high-grade soft-tissue sarcoma in the extremity or trunk : report from the National Cancer Database.
Ogura K; Fujiwara T; Healey JH
Bone Joint J; 2021 Jun; 103-B(6):1142-1149. PubMed ID: 34058874
[TBL] [Abstract][Full Text] [Related]
16. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
[TBL] [Abstract][Full Text] [Related]
17. Imaging investigations before referral to a sarcoma center delay the final diagnosis of musculoskeletal sarcoma.
Dyrop HB; Vedsted P; Rædkjær M; Safwat A; Keller J
Acta Orthop; 2017 Apr; 88(2):211-216. PubMed ID: 28077058
[TBL] [Abstract][Full Text] [Related]
18. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
